Clinical Trials · NCT02493517

Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in Acromegaly

Name: Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in Acromegaly
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 3Lanreotide

Phase: Phase 3
Recruitment status: Completed
Sponsor: Ipsen
Enrollment: 128
Start date: Oct 2014
Locations: 10 sites, China
Primary endpoint: Standardised Mean Change From Baseline in Age-adjusted IGF-1 Levels at the EOST/EW Visit

View Lanreotide compound reference